Smithfield Trust’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $256K | Sell |
332
-23
| -6% | -$17.6K | 0.01% | 333 |
|
|
2025
Q4 | $274K | Buy |
355
+10
| +3% | +$6.79K | 0.01% | 308 |
|
|
2025
Q3 | $193K | Buy |
345
+222
| +180% | +$126K | 0.01% | 351 |
|
|
2025
Q2 | $65K | Sell |
123
-14
| -10% | -$7.81K | ﹤0.01% | 523 |
|
|
2025
Q1 | $89K | Hold |
137
| – | – | ﹤0.01% | 451 |
|
|
2024
Q4 | $98K | Hold |
137
| – | – | ﹤0.01% | 451 |
|
|
2024
Q3 | $142K | Sell |
137
-4
| -3% | -$4.45K | 0.01% | 399 |
|
|
2024
Q2 | $146K | Sell |
141
-8
| -5% | -$7.75K | 0.01% | 375 |
|
|
2024
Q1 | $144K | Buy |
149
+8
| +6% | +$7.61K | 0.01% | 381 |
|
|
2023
Q4 | $125K | Hold |
141
| – | – | 0.01% | 389 |
|
|
2023
Q3 | $117K | Buy |
141
+14
| +11% | +$11K | 0.01% | 385 |
|
|
2023
Q2 | $93K | Hold |
127
| – | – | 0.01% | 444 |
|
|
2023
Q1 | $106K | Hold |
127
| – | – | 0.01% | 411 |
|
|
2022
Q4 | $93K | Hold |
127
| – | – | 0.01% | 414 |
|
|
2022
Q3 | $90K | Hold |
127
| – | – | 0.01% | 406 |
|
|
2022
Q2 | $78K | Hold |
127
| – | – | 0.01% | 461 |
|
|
2022
Q1 | $90K | Buy |
127
+23
| +22% | +$14.6K | 0.01% | 456 |
|
|
2021
Q4 | $67K | Hold |
104
| – | – | ﹤0.01% | 519 |
|
|
2021
Q3 | $64K | Hold |
104
| – | – | ﹤0.01% | 526 |
|
|
2021
Q2 | $58K | Hold |
104
| – | – | ﹤0.01% | 527 |
|
|
2021
Q1 | $50K | Hold |
104
| – | – | ﹤0.01% | 558 |
|
|
2020
Q4 | $51K | Sell |
104
-161
| -61% | -$86.9K | ﹤0.01% | 524 |
|
|
2020
Q3 | $148K | Sell |
265
-1
| -0.4% | -$606 | 0.01% | 333 |
|
|
2020
Q2 | $166K | Buy |
+266
| New | +$151K | 0.01% | 303 |
|
|
2019
Q2 | – | Sell |
-66
| Closed | -$27K | – | 981 |
|
|
2019
Q1 | $27K | Buy |
+66
| New | +$27.2K | ﹤0.01% | 565 |
|
|
2018
Q1 | – | Sell |
-76
| Closed | -$29K | – | 1090 |
|
|
2017
Q4 | $29K | Buy |
76
+7
| +10% | +$2.83K | ﹤0.01% | 612 |
|
|
2017
Q3 | $31K | Buy |
69
+15
| +28% | +$7.14K | ﹤0.01% | 592 |
|
|
2017
Q2 | $27K | Hold |
54
| – | – | ﹤0.01% | 616 |
|
|
2017
Q1 | $21K | Buy |
+54
| New | +$20K | ﹤0.01% | 636 |
|
|
2014
Q1 | – | Sell |
-24
| Closed | -$7K | – | 857 |
|
|
2013
Q4 | $7K | Buy |
+24
| New | +$6.9K | ﹤0.01% | 733 |
|
Other funds holding REGN
VCM
N
Smithfield Trust's REGN Position: Q1 2026 in Review
Smithfield Trust reduced its Regeneron Pharmaceuticals (REGN) stake by 6.5% in Q1 2026, selling an estimated $17.6K and leaving 332 shares worth $256K. The position accounts for 0.01% of the portfolio, ranked #333.
Smithfield Trust first reported a position in REGN in Q4 2013 and has held it in 30 quarters since. The position peaked at $274K in Q4 2025. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.
- Smithfield Trust held 332 shares of Regeneron Pharmaceuticals worth $256K as of Q1 2026.
- Smithfield Trust sold 23 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $17.6K.
- Regeneron Pharmaceuticals made up 0.01% of Smithfield Trust's portfolio in Q1 2026, its #333 holding.
- Smithfield Trust first reported a position in Regeneron Pharmaceuticals in Q4 2013 and has held it in 30 quarters since.
- Smithfield Trust's Regeneron Pharmaceuticals position peaked at $274K in Q4 2025.
- 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.
Based on Smithfield Trust's 13F filing for Q1 2026, filed 8 May 2026.